Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA (Centre Daily Times)
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced that oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS), has received a Fast Track designation from the U.S. Food and Drug Administration (FDA). Teva completed enrollment for the first of its two Phase III clinical trials for laquinimod ...

Abbott Receives FDA Clearance For New CELL-DYN(R) Emerald(TM) Hematology Instrument (Medical News Today)
Abbott (NYSE: ABT) announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new, compact hematology instrument, CELL-DYN Emerald(TM). Abbott's CELL-DYN Emerald will expand the company's hematology platform by offering a high performance, affordable solution for small to mid- sized clinical laboratories.